Skip to content

CytomX Therapeutics CTMX Noncash Deemed Dividend On Warrants

Noncash Deemed Dividend On Warrants at other companies

NextNav logo
NextNavNN
-$2.25M
ATN International logo
ATN InternationalATNI
$1.1M+129%
TG Therapeutics logo
TG TherapeuticsTGTX
$0
SoundHound AI, Inc. logo
SoundHound AI, Inc.SOUN
$0
KEE
Keel Infrastructure Corp. Common StockKEEL
$11.48M
IonQ logo
IonQIONQ
$7.14M-34.8%

Other financials

Income statement

See full
Revenue$10.3M-79.9%
Operating income-$19.7M-187%
Net income-$18.2M-178%
EPS (diluted)-$0.10-137%

Balance sheet

See full
Cash & equivalents$28.8M-39.4%
Total debt$2.9M-65.0%
Total equity$319.9M+1,177%
Total assets$359.4M+265%

Cash flow

See full
Operating cash flow-$25.5M-21.4%
CapEx--100%
Free cash flow-$25.5M-20.7%

Valuation

See full
Market cap$711.89M+94.8%
Enterprise value$685.92M+110%
P/S20×+17.6×

Profitability

See full
Operating margin-181.9%-206pp
Net margin-166.4%-195pp
FCF margin-225.6%-334pp

Returns & leverage

See full
Return on equity-34.3%
Debt / equity-0.3×
Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept ctmx:NoncashDeemedDividendOnWarrants.

The official record: CytomX Therapeutics’s 10-K, filed March 16, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's noncash deemed dividend on warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CytomX Therapeutics's noncash deemed dividend on warrants?
CytomX Therapeutics (CTMX) reported noncash deemed dividend on warrants of $750.5K in Q4 2025.
What does noncash deemed dividend on warrants mean?
This represents a non-cash accounting adjustment treated as a deemed dividend resulting from the modification or issuance of warrants. It reflects the economic impact of equity-linked instruments on the company's capital structure without an actual cash outflow. Investors monitor this to understand the impact of complex financial instruments on shareholder equity and earnings per share calculations.